Hanmi Pharm Co Ltd 2021 SR
The report highlights Hanmi Pharm's achievements in 2020, including recording KRW 1.0759 trillion in revenue and investing 21% of it into R&D. The company became the first in Korea to receive the 'AAA' Compliance Program grade from the Fair Trade Commission and earned an 'A' grade in the KCGS ESG evaluation. Key highlights include the development of 31 new drug pipelines, multiple orphan drug designations from the US FDA, and the opening of the Hanmi Dream Tree Nursery. The report also details the company's response to COVID-19 and its commitment to achieving a pharmaceutical powerhouse status through Creativity and Challenge.
Company: Hanmi Pharm Co Ltd
Sector: Health Care
Country: South Korea
Year: 2021
Type: SR
Pages: 49
Hanmi Pharm Co Ltd
CSR Report
The report highlights Hanmi Pharm's achievements in 2020, including recording KRW 1.0759 trillion in revenue and investing 21% of it into R&D. The company became the first in Korea to receive the 'AAA' Compliance Program grade from the Fair Trade Commission and earned an 'A' grade in the KCGS ESG evaluation. Key highlights include the development of 31 new drug pipelines, multiple orphan drug designations from the US FDA, and the opening of the Hanmi Dream Tree Nursery. The report also details the company's response to COVID-19 and its commitment to achieving a pharmaceutical powerhouse status through Creativity and Challenge.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Published
May 1, 2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women in Management
Employees